EVERFRONT BIOTECH INC.
Update：2023/06/12
Industries
Main Industry
Biotechnology
Main Product/Service
1. EF-001 (CerebracaR Wafer)
2. EF-009 Wafer
3. HK-001
4. EF-031
5. TSCA-001
6. EF-011
2. EF-009 Wafer
3. HK-001
4. EF-031
5. TSCA-001
6. EF-011
Founded Year
2010
Unified Business No.
53197299
Status
Active
Number of Employees
13
Total Paid-in
Capital
514,154,500 (NT$)
Location of Company
Taiwan
, New Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE."
Exclusive content for members
Members-only content. Please log in to access.
Introduction
Everfront Biotech Inc. (EFB) was found by the President Ho-Ching Chen and Chairman Dr. Pei-Wen Chou, and invited a group of distinguished researchers to form a research team for new drug discovery and development. This team included Professor Shinn-Zong Lin, the Superintendent of Hualien Tzu Chi Hospital, Professor Horng-Jyh Harn, the associate vice president of Bioinnovation Center in Tzu Chi foundation, Professor Tzyy-Wen Chiou from Dong-Hua University, and Dr. Tza-Zen Chaung. The establishment of this team marked a new era for the company’s drug discovery and development.
We are developing small molecules that have the potential to bring safe and effective treatments for the patients with cancers, neuronal degenerative diseases and rare diseases. Our team is specialized in pre-clinical study design, CMC；Chemistry, Manufacturing, and Control, IND-submission, and the clinical trial design and conduction.
Up to now, total three clinical trials are performing in Taiwan under the approval of USFDA and TFDA. Besides, five more products are under the pre-clinical status. Progressively, we are devoted in developing the technology that have commercial application potentials to help the people with urgent medical needs.
We are developing small molecules that have the potential to bring safe and effective treatments for the patients with cancers, neuronal degenerative diseases and rare diseases. Our team is specialized in pre-clinical study design, CMC；Chemistry, Manufacturing, and Control, IND-submission, and the clinical trial design and conduction.
Up to now, total three clinical trials are performing in Taiwan under the approval of USFDA and TFDA. Besides, five more products are under the pre-clinical status. Progressively, we are devoted in developing the technology that have commercial application potentials to help the people with urgent medical needs.
